eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
6/2008
vol. 46
 
Share:
Share:
more
 
 
abstract:

Review paper
Efficacy and safety of TNF blockers in ankylosing spondylitis in randomized, controlled trials and prolonged open label studies

Ewa Stanisławska-Biernat

Reumatologia 2008; 46, 6: 361–366
Online publish date: 2009/01/21
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Ankylosing spondylitis (AS) is a chronic inflammatory disease in the course of which we observe diminution of range of motion of the spine and invalidity. Randomized controlled trials and prolonged open label studies have confirmed the efficacy and safety of a new group of drugs in treatment of ankylosing spondylitis. By means of a variety of mechanisms, TNF inhibitors reduce activity of one of the proinflammatory cytokines, TNF-α. This article presents a systematic review of published trials, the results of which prove the superiority of adalimumab, etanercept and infliximab over traditional methods of treatment. Introduction of TNF blockers represents a major advance in therapy of ankylosing spondylitis.
keywords:

ankylosing spondylitis, treatment, TNF blockers, randomized controlled trials, etanercept, adalimumab, infliximab



Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe